Kura Oncology to Report Third Quarter 2024 Financial Results

Core Insights - Kura Oncology, Inc. will report its third quarter 2024 financial results on November 7, 2024, after U.S. market close [1] - A conference call and webcast will be held at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update [1][2] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment [3] - The company's pipeline includes small molecule drug candidates targeting cancer signaling pathways, with ziftomenib being a key candidate for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) [3] - Ziftomenib has received Breakthrough Therapy Designation and is currently in a Phase 2 registration-directed trial (KOMET-001) [3] - Kura is also evaluating KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial [3] - Tipifarnib is in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma [3]